Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Highlights New Data on VYKAT (TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference Provided by GlobeNewswire Jun 25, 2025, 5:00:00 AM ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD ...

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

What’s becoming clear is that obesity isn’t one disease — it’s many, said Jack Yanovski, a senior obesity researcher at the ...

The conference represents a unique collaboration between the Prader-Willi Syndrome Association | USA (PWSA | USA), the Foundation for Prader-Willi Research (FPWR), and the International Prader-Willi ...

In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number ...

TD Cowen analyst Tyler Van Buren initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $110 price target The firm says Vykat XR ...

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...